REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
25/05/2026
Voltar para busca
Dado oficial do USPTO
TANVEX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
56
Atualização mais recente
26/05/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
03/02/2017
Data de registro
25/05/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
25/05/2021
Última transação
26/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Código do desenho
5
Tipo de titular
03
Localização do titular
Grand Cayman, KY
Examinador
SCHMIDT, JOHN JOSEPH
Unidade examinadora
N10
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the word "TANVEX" in the color light blue in stylized typeface.
Titulares e representantes
Titulares
Tanvex BioPharma, Inc.
Representantes
Dyan M. House Baker & McKenzie LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-arthritis preparations; anti-inflammatory agent; anticancer drug; antirheumatic preparations; medicines for human purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; western medicines for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; medicinal agent for human use, namely, medicinal herbal preparations; biological preparations for medical purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; haematogen, namely, blood substitutes for human use; chemical preparations for medical purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; pharmaceutical drugs for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; pharmaceutical preparations for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis
Publicações
Histórico de despachos e eventos da marca no USPTO.
56 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
25/05/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/03/2021
PUBO
PUBLISHED FOR OPPOSITION
09/03/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17/02/2021
IUCN
NOTICE OF ALLOWANCE CANCELLED
11/01/2021
ATRQ
ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED
04/01/2021
PCBG
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
04/01/2021
APET
ASSIGNED TO PETITION STAFF
04/01/2021
TPAD
TEAS PETITION TO AMEND BASIS RECEIVED
18/12/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
28/07/2020
EX5G
SOU EXTENSION 5 GRANTED
27/07/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
23/07/2020
EXT5
SOU EXTENSION 5 FILED
02/07/2020
EEXT
SOU TEAS EXTENSION RECEIVED
02/07/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/07/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/07/2020
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
02/07/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/07/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/07/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/07/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
31/12/2019
EX4G
SOU EXTENSION 4 GRANTED
27/12/2019
EXT4
SOU EXTENSION 4 FILED
27/12/2019
EEXT
SOU TEAS EXTENSION RECEIVED
27/12/2019
DOCK
ASSIGNED TO EXAMINER
08/07/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/06/2019
EX3G
SOU EXTENSION 3 GRANTED
05/06/2019
EXT3
SOU EXTENSION 3 FILED
05/06/2019
EEXT
SOU TEAS EXTENSION RECEIVED
05/06/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
26/12/2018
EX2G
SOU EXTENSION 2 GRANTED
24/12/2018
EXT2
SOU EXTENSION 2 FILED
24/12/2018
EEXT
SOU TEAS EXTENSION RECEIVED
24/12/2018
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/05/2018
EX1G
SOU EXTENSION 1 GRANTED
02/05/2018
EXT1
SOU EXTENSION 1 FILED
02/05/2018
EEXT
SOU TEAS EXTENSION RECEIVED
02/05/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/05/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/01/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
14/11/2017
PUBO
PUBLISHED FOR OPPOSITION
14/11/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
25/10/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/10/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/09/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/09/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/09/2017
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
06/05/2017
GPRA
PRIORITY ACTION E-MAILED
06/05/2017
CPRA
PRIORITY ACTION WRITTEN
06/05/2017
DOCK
ASSIGNED TO EXAMINER
29/04/2017
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
30/03/2017
ALIE
ASSIGNED TO LIE
10/03/2017
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
23/02/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/02/2017
NWAP
NEW APPLICATION ENTERED
07/02/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TANVEX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.